Boston Scientific (NYSE: BSX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.47 per share a year ago.

Amy DuRoss, a director at $BLFS, sold 5,632 shares of the company on 03-14-2025 for an estimated $140,574. We received data on the trade from a recent SEC filing ...

Sarah Aebersold, the Chief Human Resources Officer of $BLFS, sold 198 shares of the company on 07-07-2025 for an estimated $4,409. We received data on the trade from ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F ...

Despite interesting tailwinds in its biopreservation businesses, there are factors of risk with BioLife's growth outlook. Valuations are unsupportive and suggest BioLife could potentially be priced at ...

BioLife Solutions, Inc. (BLFS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

An acquisition spree has produced a host of problems, costs, write-offs, a collapse in gross margins and profits, cash bleed, and significant dilution. While only the evo and Sexton acquisitions have ...

Shares of BioLife Solutions, Inc. (BLFS) have gained 1.6% over the past four weeks to close the last trading session at $22.37, but there could still be a solid upside left in the stock if short-term ...

Conestoga Capital Advisors, an asset management company, released its “Conestoga Micro Cap Growth Fund” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, ...